Clinical Trials News

MANHASSET, N.Y.--(BUSINESS WIRE)--Researchers at Northwell Health’s Feinstein Institutes for Medical Research found that obinutuzumab, a therapeutic antibody that depletes B cells and is approved for the treatment of B cell malignancies, benefitted patients with lupus nephritis, a severe complication of lupus that compromises kidney function. The study, which was led by Richard A. Furie, MD, professor in the Feinstein Institutes’ Institute of Molecular Medicine and The Marilyn and Barry Rubenst...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company’s common stock to six newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of...

CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA tissue technology more than two d...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 12, 2025, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France....

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications...

LOS ANGELES--(BUSINESS WIRE)--Researchers with City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, will present the latest cancer research at the AACR Annual Meeting 2025, which will take place April 25 to 30 in Chicago. City of Hope experts will present more than 74 chaired, plenary, educational, minisymposium, poster and other sessions...

BOSTON & STAFFORDSHIRE, England--(BUSINESS WIRE)--Following the FDA’s recent announcement expanding flexibility in preclinical submission evidence, Instem is reaffirming its role as the industry’s trusted provider of an end-to-end preclinical platform - empowering life sciences organizations with the tools, insight, and scientific depth needed to thrive in an increasingly dynamic regulatory environment. While many view this shift by the FDA as a new direction, Instem sees it as a natural progre...

PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics to present at inaugural Centri Capital Conference at Nasdaq on April 22, 2025....

LAUSANNE, Switzerland--(BUSINESS WIRE)--Timeline®, the Swiss consumer biotech company at the forefront of longevity research, has launched Mitopure® Gummies, a new, convenient format of its Urolithin A supplement containing a patented and pure form of this powerful postbiotic. Mitopure Gummies support cellular health by helping remove damaged mitochondria and waste (a process called mitophagy) and create new, healthy mitochondria, improving the cell’s ability to produce energy, which often tran...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs....